Chromatin-based treatments for affective disorders - insight or Utopia

Depression: From Psychopathology to Pharmacotherapy

Volumn 27, Issue , 2010, Pages 182-198

  Covington, Herbert E ^a   Berton, Olivier ^b  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872247366     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000319526     Document Type: Chapter

References (49)

1. Cohen S, Greenberg ME: Communication between the synapse and the nucleus in neuronal development, plasticity, and disease. Annu Rev Cell Dev Biol 2008;24:183-209.
2. Mill J, Petronis A: Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 2007;12:799-814.
3. Grayson DR, Kundakovic M, Sharma RP: Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 2010;77:126-135.
4. Bird A: Perceptions of epigenetics. Nature 2007;447:396-398.
5. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A: An operational definition of epigenetics. Genes Dev 2009;23:781-783.
6. Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P: Decoding the epigenetic language of neuronal plasticity. Neuron 2008;60:961-974.
7. Hemberger M, Dean W, Reik W: Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. Nat Rev Mol Cell Biol 2009;10:526-537.
8. Youngson NA, Whitelaw E: Transgenerational epigenetic effects. Annu Rev Genomics Hum Genet 2008;9:233-257.
9. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, Jaenisch R, Laird PW, Akbarian S: DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2007;2:e895.
10. Herrup K, Yang Y: Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 2007;8:368-378.
11. Berger SL: The complex language of chromatin regulation during transcription. Nature 2007;447:407-412.
12. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J, Zhang Y: New nomenclature for chromatin-modifying enzymes. Cell 2007;131:633-636.
13. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-254.
14. Suzuki MM, Bird A: DNA methylation landscapes:provocative insights from epigenomics. Nat Rev Genet 2008;9:465-476.
15. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in neurological diseases:genes, syndromes, and therapies. Lancet Neurol 2009;8:1056-1072.
16. Zhang TY, Meaney MJ: Epigenetics and the environmental regulation of the genome and its function. Annu Rev Psychol 2010;61:439-466, C431-C433.
17. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, Turecki G, Meaney MJ: Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12:342-348.
18. Bienvenu T, Chelly J: Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat Rev Genet 2006;7:415-426.
19. Sharma RP, Grayson DR, Guidotti A, Costa E: Chromatin, DNA methylation and neuron gene regulation-The purpose of the package. J Psychiatry Neurosci 2005;30:257-263.
20. Feng J, Fouse S, Fan G: Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 2007;61:58R-63R.
21. Tsankova N, Renthal W, Kumar A, Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355-367.
22. Kazantsev AG, Thompson LM: Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008;7:854-868.
23. Akhtar MW, Raingo J, Nelson ED, Montgomery RL, Olson EN, Kavalali ET, Monteggia LM: Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J Neurosci 2009;29:8288-8297.
24. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ: Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006;311:864-868.
25. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9:519-525.
26. Schroeder FA, Lin CL, Crusio WE, Akbarian S: Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007;62:55-64.
27. Bouchain G, Delorme D: Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem 2003;10:2359-2372.
28. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103:1587-1592.
29. Onishchenko N, Karpova N, Sabri F, Castren E, Ceccatelli S: Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. J Neurochem 2008;106:1378-1387.
30. Covington HE 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, Fass DM, Renthal W, Rush AJ 3rd, Wu EY, Ghose S, Krishnan V, Russo SJ, Tamminga C, Haggarty SJ, Nestler EJ: Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009;29:11451-11460.
31. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-2046.
32. Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH: Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007;16:1293-1306.
33. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH: HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009;459:55-60.
34. Roozendaal B, Hernandez A, Cabrera SM, Hagewoud R, Malvaez M, Stefanko DP, Haettig J, Wood MA: Membrane-associated glucocorticoid activity is necessary for modulation of long-term memory via chromatin modification. J Neurosci 2010;30:5037-5046.
35. Akbarian S: The molecular pathology of schizophrenia-focus on histone and DNA modifications. Brain Res Bull 2009, E-pub ahead of print.
36. Akbarian S, Huang HS: Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry 2009;65:198-203.
37. Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker SP, Roberts RC, Bunney WE Jr, Conley RC, Jones EG, Tamminga CA, Guo Y: Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2005;62:829-840.
38. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406:593-599.
39. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T: A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004;18:1251-1262.
40. Maze I, Covington HE 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A, Nestler EJ: Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 2010;327:213-216.
41. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-326.
42. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA: Histone demethylation mediated by the nuclear amine oxidase homolog lsd1. Cell 2004;119:941-953.
43. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN: Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase b in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003;60:804-815.
44. Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, Ernst N, Quirion R, Gratton A, Szyf M, Turecki G: Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase b in the frontal cortex of suicide completers. Arch Gen Psychiatry 2009;66:22-32.
45. Wilkinson MB, Xiao G, Kumar A, LaPlant Q, Renthal W, Sikder D, Kodadek TJ, Nestler EJ: Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 2009;29:7820-7832.
46. Covington HE, Maze I, Bradbury K, Sun H, Mouzon E, Ghose S, Tamminga C, Neve RL, Nestler EJ: A role for repressive histone methylation in cocaineinduced vulnerability to stress. Society for Neuroscience Annual Meeting list of abstracts, 2010.
47. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S: Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 2007;27:11254-11262.
48. Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, Szyf M, Anisman H. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry. 2008;64:645-652.
49. Ernst C, Chen ES, Turecki G: Histone methylation and decreased expression of TrkB.T1 in orbital frontal cortex of suicide completers. Mol Psychiatry 2009;14:830-832.